stockportfolio.pro
Cytokinetics, Incorporated P/E Ratio 1999–2025
Cytokinetics, Incorporated (CYTK) annual price-to-earnings ratio by fiscal year, computed from SEC filings. Compound growth +13.5%/yr over 26 years.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | — | — |
| FY 2024 | — | — |
| FY 2023 | — | — |
| FY 2022 | — | — |
| FY 2021 | — | — |
| FY 2020 | — | — |
| FY 2019 | — | — |
| FY 2018 | — | — |
| FY 2017 | — | — |
| FY 2016 | 31.15 | — |
| FY 2015 | — | — |
| FY 2014 | — | — |
| FY 2013 | — | — |
| FY 2012 | — | — |
| FY 2011 | — | — |
| FY 2010 | — | — |
| FY 2009 | 1.15 | — |
| FY 2008 | — | — |
| FY 2007 | — | — |
| FY 2006 | — | — |
| FY 2005 | — | — |
| FY 2004 | — | — |
| FY 2003 | — | — |
| FY 2002 | — | — |
| FY 2001 | — | — |
| FY 2000 | — | — |
| FY 1999 | — | — |
Source: Cytokinetics, Incorporated SEC filings — fiscal-year-end price ÷ diluted EPS. Refreshed nightly.
See the full picture for Cytokinetics, Incorporated
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeCytokinetics, Incorporated — frequently asked questions
What is Cytokinetics, Incorporated's price-to-earnings ratio?
Cytokinetics, Incorporated (CYTK) reported price-to-earnings ratio of 31.15 for fiscal year 2016, per its SEC filings.
How has Cytokinetics, Incorporated's price-to-earnings ratio changed over time?
Between fiscal 1999 and 2025, CYTK's price-to-earnings ratio grew at roughly 13.5% per year (compound annual rate), from 1.15 to 31.15.
Where does this data come from?
Figures are computed from Cytokinetics, Incorporated's official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.